At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 238 enrolled
Drug / intervention
Mepolizumab +1 moredrug
Likely dose
Mepolizumab 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised Controlled Trial of Mepolizumab Initiated Following Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD
In Brief
A Phase 3 clinical trial evaluating Mepolizumab and Placebo for COPD and Eosinophilia. Completed, enrolled 238 participants across 1 site.
Detailed Summary
This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD, Eosinophilia
CountriesUnited Kingdom
CollaboratorsGlaxoSmithKline
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartSep 2020
Primary CompletionJun 2024
TodayJul 2026
First PostedAug 30, 2019
Enrollment StartSep 7, 2020
Primary CompletionJun 21, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.8 years ago
Interventions
Mepolizumabdrug
Mepolizumab 100mg subcutaneous injection
Placebodrug
Saline solution for subcutaneous injection